Naftin (Naftifine HCl) Patent Expiration, LOE Window & CMS Spending

Naftin (Naftifine HCl) by Legacy Sezc: FDA Orange Book LOE 2033-01-31, 3 AB generics, $1.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLegacy Sezc
FDA Application & PathwayN019599 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-01-31
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$1.1M
2024 Medicare Part D Spend$776K
2024 Medicaid Spend$363K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel